In an updated evaluation, Truist Securities has adjusted its price target for Boston Scientific (BSX, Financial), bringing it down to $113 from a previous $120, while maintaining a Buy rating. This revision is part of a comprehensive analysis in anticipation of the company's first-quarter performance within the Medical Technology sector.
Boston Scientific's revenue and earnings are seen as less vulnerable compared to some other sub-sectors within the medical field. This resilience may sustain investor interest, despite challenges such as tariff fluctuations affecting the broader industry. However, there is caution around the 2025 outlooks as companies are expected to factor in some macroeconomic uncertainties into their projections.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 29 analysts, the average target price for Boston Scientific Corp (BSX, Financial) is $116.69 with a high estimate of $130.00 and a low estimate of $84.11. The average target implies an upside of 25.96% from the current price of $92.64. More detailed estimate data can be found on the Boston Scientific Corp (BSX) Forecast page.
Based on the consensus recommendation from 34 brokerage firms, Boston Scientific Corp's (BSX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Boston Scientific Corp (BSX, Financial) in one year is $76.94, suggesting a downside of 16.95% from the current price of $92.64. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Boston Scientific Corp (BSX) Summary page.
